Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

72 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Type 2 innate lymphoid cells are not involved in mouse bladder tumor development.
Schneider AK, Domingos-Pereira S, Cesson V, Polak L, Fallon PG, Zhu J, Roth B, Nardelli-Haefliger D, Derré L. Schneider AK, et al. Among authors: nardelli haefliger d. Front Immunol. 2024 Jan 12;14:1335326. doi: 10.3389/fimmu.2023.1335326. eCollection 2023. Front Immunol. 2024. PMID: 38283350 Free PMC article.
Immunotherapeutic strategies for bladder cancer.
Chevalier MF, Nardelli-Haefliger D, Domingos-Pereira S, Jichlinski P, Derré L. Chevalier MF, et al. Hum Vaccin Immunother. 2014;10(4):977-81. doi: 10.4161/hv.27621. Epub 2014 Jan 2. Hum Vaccin Immunother. 2014. PMID: 24384699 Free PMC article.
Vδ2 T cells are associated with favorable clinical outcomes in patients with bladder cancer and their tumor reactivity can be boosted by BCG and zoledronate treatments.
Nguyen S, Chevalier MF, Benmerzoug S, Cesson V, Schneider AK, Rodrigues-Dias SC, Dartiguenave F, Lucca I, Jichlinski P, Roth B, Nardelli-Haefliger D, Derré L. Nguyen S, et al. Among authors: nardelli haefliger d. J Immunother Cancer. 2022 Aug;10(8):e004880. doi: 10.1136/jitc-2022-004880. J Immunother Cancer. 2022. PMID: 36002184 Free PMC article.
Tumor-Microenvironment Characterization of the MB49 Non-Muscle-Invasive Bladder-Cancer Orthotopic Model towards New Therapeutic Strategies.
Domingos-Pereira S, Sathiyanadan K, Polak L, Haefliger JA, Schmittnaegel M, Ries CH, Jichlinski P, Roth B, Derré L, Nardelli-Haefliger D. Domingos-Pereira S, et al. Among authors: nardelli haefliger d. Int J Mol Sci. 2022 Dec 21;24(1):123. doi: 10.3390/ijms24010123. Int J Mol Sci. 2022. PMID: 36613562 Free PMC article.
Intravesical Ty21a treatment of non-muscle invasive bladder cancer induces immune responses that correlate with safety and may be associated to therapy potential.
Derré L, Lucca I, Cesson V, Bohner P, Crettenand F, Rodrigues-Dias SC, Dartiguenave F, Masnada A, Teixeira-Pereira C, Benmerzoug S, Chevalier MF, Domingos-Pereira S, Nguyen S, Polak L, Schneider AK, Jichlinski P, Roth B, Nardelli-Haefliger D. Derré L, et al. Among authors: nardelli haefliger d. J Immunother Cancer. 2023 Dec 14;11(12):e008020. doi: 10.1136/jitc-2023-008020. J Immunother Cancer. 2023. PMID: 38101861 Free PMC article.
72 results